Verona Pharma Announces December 2024 Investor Conference Participation

Rhea-AI Summary

Verona Pharma (Nasdaq: VRNA) announces its participation in two major healthcare investor conferences in December 2024. The company will present at the Piper Sandler 36th Annual Healthcare Conference in New York on December 3 at 12:00 p.m. ET, and at the 7th Annual Evercore HealthCONx Conference in Miami on December 4 at 3:00 p.m. ET. Webcasts of both presentations will be available on the company's website. Verona Pharma specializes in developing therapies for chronic respiratory diseases, with their first commercial product Ohtuvayre™ (ensifentrine) being a dual-action COPD treatment.

LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024:

Piper Sandler 36^th Annual Healthcare Conference
Date: Tuesday, December 3, 2024
Time: 12:00 p.m. ET / 5:00 p.m. GMT
Location: New York, NY

7^th Annual Evercore HealthCONx Conference
Date: Wednesday, December 4, 2024
Time: 3:00 p.m. ET / 8:00 p.m. GMT
Location: Miami, FL

A webcast of each conference presentation will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc	Tel: +1-844-341-9901
Victoria Stewart, Senior Director of Investor Relations and Communications	IR@veronapharma.com
Argot Partners (US Investor Enquiries)	Tel: +1-212-600-1902 verona@argotpartners.com
Ten Bridge Communications International / US Media Enquiries	Tel: +1-781-316-4424 tbcverona@tenbridgecommunications.com
Wendy Ryan

About Verona Pharma

Verona Pharma is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. Ohtuvayre™ (ensifentrine) is the Company’s first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory activities in one molecule. Ensifentrine has potential applications in non-cystic fibrosis bronchiectasis, cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

FAQ

When is Verona Pharma (VRNA) presenting at the Piper Sandler Healthcare Conference in 2024?

Verona Pharma (VRNA) will present at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 12:00 p.m. ET in New York.

Where can I watch Verona Pharma's (VRNA) December 2024 investor conference presentations?

Webcasts of Verona Pharma's conference presentations will be available on the Events and Presentations section of the company's website at www.veronapharma.com.

What conferences is Verona Pharma (VRNA) attending in December 2024?

Verona Pharma is attending two conferences in December 2024: the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, and the 7th Annual Evercore HealthCONx Conference in Miami on December 4.